Therapeutic applications oftrans-splicing
Author(s) -
Elizabeth M Hong,
Carin K. Ingemarsdotter,
Andrew Lever
Publication year - 2020
Publication title -
british medical bulletin
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.08
H-Index - 112
eISSN - 1471-8391
pISSN - 0007-1420
DOI - 10.1093/bmb/ldaa028
Subject(s) - rna splicing , trans splicing , exon , alternative splicing , computational biology , exon skipping , minigene , biology , rna , gene , genetics
Background RNA trans-splicing joins exons from different pre-mRNA transcripts to generate a chimeric product. Trans-splicing can also occur at the protein level, with split inteins mediating the ligation of separate gene products to generate a mature protein. Sources of data Comprehensive literature search of published research papers and reviews using Pubmed. Areas of agreement Trans-splicing techniques have been used to target a wide range of diseases in both in vitro and in vivo models, resulting in RNA, protein and functional correction. Areas of controversy Off-target effects can lead to therapeutically undesirable consequences. In vivo efficacy is typically low, and delivery issues remain a challenge. Growing points Trans-splicing provides a promising avenue for developing novel therapeutic approaches. However, much more research needs to be done before developing towards preclinical studies. Areas timely for developing research Increasing trans-splicing efficacy and specificity by rational design, screening and competitive inhibition of endogenous cis-splicing.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom